• Sustainability
  • Partnerships
  • News
logo
  • Company
    • About us
    • Leadership
    • Impact
  • Therapies
    • Reimagining pain relief
    • EXPAREL
    • iovera
    • ZILRETTA
  • Innovation
    • Pipeline
    • PCRX-201
    • Clinical trials
    • pMVL technology
  • Patients
    • Explore insights
    • Understand pain
    • Plan ahead
    • Get involved
  • Careers
    • Life at Pacira
    • Benefits
    • Open positions
  • Investors
    • Overview
    • Events
    • SEC filings
    • Analyst coverage
    • Corporate governance
    • Investor toolkit
    • Investor FAQ
logo
  • Company
    • About us
    • Leadership
    • Impact
  • Therapies
    • Reimagining pain relief
    • EXPAREL
    • iovera
    • ZILRETTA
  • Innovation
    • Pipeline
    • PCRX-201
    • Clinical trials
    • pMVL technology
  • Patients
    • Explore insights
    • Understand pain
    • Plan ahead
    • Get involved
  • Careers
    • Life at Pacira
    • Benefits
    • Open positions
  • Investors
    • Overview
    • Events
    • SEC filings
    • Analyst coverage
    • Corporate governance
    • Investor toolkit
    • Investor FAQ
  • Sustainability
  • Partnerships
  • News

EXPAREL® (bupivacaine liposome injectable suspension), ioveraoo, ZILRETTA® (triamcinolone acetonide extended-release injectable suspension), and Pacira are registered trademarks of the respective subsidiaries of Pacira BioSciences, Inc. All other trademarks referenced herein are the property of their respective owners.

x icon
  • Contact
  • Legal
  • Sitemap
  • Privacy Notice
  • Terms of Use
  • Accessibility Statement

©2025 Pacira Pharmaceuticals, Inc., a wholly owned subsidiary of Pacira BioSciences, Inc. PP-MP-US-0289

Cookies are used on this site to assist in continually improving the candidate experience and all the interaction data we store of our visitors is anonymous. Learn more about your rights on our Privacy Policy page.

Okay